Business
Key SIRT6 Patent Application
Key SIRT6 Patent Application.
About this update from Genflow Biosciences Plc
[{"type":"text","content":"\n\n15 May 2025\n \nGenflow Biosciences plc\n \nGenflow Biosciences Announces Progress of Key SIRT6 Patent Application in Japan\n \nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), the only publicly listed longevity company in Europe, announces that the Japanese Patent Office has advanced its SIRT6-related patent application (Application No. JP 2024515284) to the national examination phase.\n \nThe application, titled \"Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases,\" was originally filed on 13 May 2022 and is jointly owned by the University of Rochester, The Trustees of Columbia University in the City of New York, and Albert Einstein College of Medicine. Genflow holds the exclusive license to this intellectual property.\n \nThe invention covers novel SIRT6 gene variants that play a central role in genomic stability, metabolic regulation, and healthy aging. These variants underpin Genflow's core therapeutic platform and represent a key part of its pipeline targeting age-related diseases.\n \nThe progression to national examination in Japan marks an important step in Genflow's strategy to establish broad international patent protection. Japan, with one of the world's most rapidly aging populations, is a priority market for longevity-related innovation.\n \nDr. Eric Leire, CEO of Genflow Biosciences, commented: \"We are pleased to see continued momentum in the protection of our SIRT6 intellectual property. Japan represents a strategically important jurisdiction for Genflow, and advancing this patent application strengthens our global positioning as a leader in longevity gene therapy.\"\n \nGenflow continues to progress its preclinical and clinical programs targeting age-related pathologies using the SIRT6 gene variants.\n \nContacts\n\n\n\n\nGenflow Biosciences\n\n\nHarbor Access\n\n\n\n\nDr Eric Leire, CEO\n\n\nJonathan Paterson, Investor Relations\n\n\n\n\n+32-477-495-881\n\n\n+1 475 477 9401\n\n\n\n\n\n\n\[email protected]\n\n\n\n\nCorporate Brokers\n\n\n\n\n\n\n\nCapital Plus Partners Ltd\n\n\n \n\n\n\n\nJon Critchley, +44 0203 821 6168\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nAbout Genflow Biosciences\n \nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB...